Amlodipine for early-stage endometrial cancer in women under 45
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if the blood pressure drug amlodipine can treat early-stage endometrial cancer in women under 45 who want to preserve fertility. It may be an option for those whose cancer hasn't fully responded to initial hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a low-grade (G1 or G2) endometrial cancer that has not spread deep into the muscle layer of the uterus (stage IA).
- You are 45 years old or younger and wish to keep the ability to have children.
- You have not had low blood pressure (hypotension) more than three times in the last six months.
- You have not taken any other blood pressure medications regularly.
- You are either starting treatment for the first time or have had partial success with a 12- or 24-week course of hormone therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding orlistat to standard hormone therapy for people with early endometrial cancer or atypical hyperplasia who have not fully responded to initial hormone treatment. It aims to preserve fertility and avoid hysterectomy.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial tests a new drug, cadonilimab (AK104), combined with chemotherapy for women with advanced or recurrent endometrial cancer. The goal is to see if the combination can help shrink or control the cancer.
This trial tests whether using tumor “molecular” results plus standard risk factors can guide the best type and timing of radiation after surgery for early-stage endometrial cancer. It may help you avoid under- or overtreatment by matching radiotherapy to your specific risk.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.